Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.